Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms - PubMed (original) (raw)

Comparative Study

Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms

H L Wilson et al. J Med Genet. 2003 Aug.

Abstract

Methods: The 22q13 deletion syndrome (MIM 606232) is characterised by moderate to profound mental retardation, delay/absence of expressive speech, hypotonia, normal to accelerated growth, and mild dysmorphic features. We have determined the deletion size and parent of origin in 56 patients with this syndrome.

Results: Similar to other terminal deletion syndromes, there was an overabundance of paternal deletions. The deletions vary widely in size, from 130 kb to over 9 Mb; however all 45 cases that could be specifically tested for the terminal region at the site of SHANK3 were deleted for this gene. The molecular structure of SHANK3 was further characterised. Comparison of clinical features to deletion size showed few correlations. Some measures of developmental assessment did correlate to deletion size; however, all patients showed some degree of mental retardation and severe delay or absence of expressive speech, regardless of deletion size.

Conclusion: Our analysis therefore supports haploinsufficiency of the gene SHANK3, which codes for a structural protein of the postsynaptic density, as a major causative factor in the neurological symptoms of 22q13 deletion syndrome.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Am J Med Genet. 2000 Feb 28;90(5):382-5 - PubMed
    1. Prenat Diagn. 2000 Jan;20(1):76-9 - PubMed
    1. Am J Med Genet. 2000 Dec 4;96(6):839-44 - PubMed
    1. Clin Genet. 2000 Dec;58(6):483-7 - PubMed
    1. Am J Med Genet. 2001 Jun 15;101(2):91-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources